European specialty pharmaceutical company focused on central nervous system (CNS) disorders Neuraxpharm Group announced on Tuesday that it has acquired Provigil (modafinil) and Nuvigil (armodafinil) as of December 2024.

Both drugs are indicated for treating Excessive Daytime Sleepiness (EDS) in adults with narcolepsy. Provigil is primarily sold in Europe, with notable markets in France, Spain and Italy, while Nuvigil has significant sales in Australia and Mexico. These products align with Neuraxpharm's strategy to expand its CNS portfolio and increase patient access worldwide.

The acquisition facilitates entry into new regions like Australia and strengthens Neuraxpharm's presence in Mexico, where the company established an office in 2023. This deal follows Neuraxpharm's 2023 acquisition of product portfolios from Sanofi and its partnership with TG Therapeutics for the commercialization of ublituximab. Neuraxpharm also acquired Buccolam, a leading child epilepsy treatment, in 2020. Financial terms of the transaction have not been disclosed.